Objectives The central nervous system is a significant extraglandular target in primary Sjögren’s syndrome (pSS), often ...

Objectives Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterised by multiorgan involvement.

In lupus, TLR7 and TLR9 mediate loss of tolerance to RNA and DNA, respectively. Yet, TLR7 promotes while TLR9 protects from disease, implying differences in signaling. To dissect this ‘TLR paradox’, ...

Objective We investigated DORIS (Definition of Remission in SLE) attainment in patients with SLE in the placebo-controlled phase 3 TULIP long-term extension (LTE) trial of anifrolumab. DORIS ...

Bone involvement is a common cause of morbidity and disability in systemic lupus erythematosus (SLE). 1 This is both a consequence of the disease itself and treatments, including steroids. 2 As ...

Wang W, He S, Zhang W, et al. BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: A Phase 1 open-label clinical trial. Ann Rheum Dis. 2024 doi: 10.1136/ard-2024-225785. Learning ...

Immune dysregulation in systemic lupus erythematosus (SLE) results in the autoimmune manifestations of SLE, but also leads to an impaired immune response to pathogens and vulnerability to infections ...

Systemic lupus erythematosus (SLE) is a clinically and immunologically heterogeneous autoimmune disease that can be challenging to diagnose, especially in its early stages. Although developed in the ...

Background Persistent production of type I interferons (IFN-Is) is one of the hallmarks of lupus skin disease that is exacerbated by ultraviolet (UV) light. We previously showed IFN-I induction by UV ...

Background Kidney involvement is common in lupus. Lupus and kidney diseases incur poor outcomes in people from racial/ethnic minority groups. Previous studies have utilized the national registry of ...

Objective Patients with lupus erythematosus (LE) are at heightened risk for clinical events, chiefly heart attacks and strokes, from atherosclerotic cardiovascular disease (ASCVD). We recently ...

Background In AURORA 1, adding voclosporin to mycophenolate mofetil (MMF) and low-dose steroids led to signficant reductions in proteinuria at one year in patients with lupus nephritis (LN). We report ...